Hong Kong Healthtech Stock News

JD Health International Inc. ( HKG:6618 ) saw a double-digit share price rise of over 10% in the past couple of months...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares. See our latest analysis for Alebund Pharmaceuticals (Jiangsu). The strong first day reception for Alebund Pharmaceuticals (Jiangsu) has been followed by a 1 day share price return of 18.75% to HK$30.28, although the share price return year to date is down 34.17%. This suggests short term momentum is...

Swire Properties Limited ( HKG:1972 ) saw significant share price movement during recent months on the SEHK, rising to...

COSCO SHIPPING Ports Limited ( HKG:1199 ), might not be a large cap stock, but it saw significant share price movement...

What changed at NetEase and why it matters for shareholders NetEase (SEHK:9999) recently approved a Third Amended and Restated Memorandum and Articles of Association at its 2026 Annual General Meeting, a governance update that helps frame how investors may view the stock’s latest move. The bylaw changes came shortly after NetEase stock gained 7.32% over the past week, following quarterly earnings of HK$4.03 per share versus an estimated HK$3.42, a 17.77% difference that has drawn fresh...

Hysan Development Company Limited ( HKG:14 ), is not the largest company out there, but it saw significant share price...

Even though Honma Golf Limited's ( HKG:6858 ) recent earnings release was robust, the market didn't seem to notice. Our...

Legendary Education Group Limited's ( HKG:8195 ) recent earnings report didn't offer any surprises, with the shares...

The investors in Precision Tsugami (China) Corporation Limited 's ( HKG:1651 ) will be rubbing their hands together...

Despite posting healthy earnings, China High Speed Transmission Equipment Group Co., Ltd.'s ( HKG:658 ) stock has been...

As you might know, China Water Affairs Group Limited ( HKG:855 ) recently reported its full-year numbers. Statutory...

Shougang Fushan Resources Group Limited ( HKG:639 ) is about to trade ex-dividend in the next 4 days. Typically, the...

It looks like China Taiping Insurance Holdings Company Limited ( HKG:966 ) is about to go ex-dividend in the next four...

Those following along with Texwinca Holdings Limited ( HKG:321 ) will no doubt be intrigued by the recent purchase of...

GSMA membership and AI focused network upgrade reshape the China Tower story China Tower (SEHK:788) has joined the GSMA and completed a nationwide upgrade that turns 5.6 million base stations and 2.1 million tower sites into intelligent edge computing hubs for connectivity in the AI era. See our latest analysis for China Tower. Despite the AI focused upgrade and GSMA membership, China Tower’s recent share price momentum has softened, with the stock at HK$9.04 and the 1 month share price...

CITIC (SEHK:267) drew investor attention after its 26 June 2026 AGM, where the company declared a 2025 final dividend of RMB 0.385 per share, payable in either RMB or Hong Kong dollars. See our latest analysis for CITIC. While the 2025 final dividend announcement has focused attention on income, CITIC’s 1 month share price return is down 20.98% and the year to date share price return is down 13%, even as the 5 year total shareholder return of 83.56% points to a much stronger long term...

CARsgen Therapeutics Holdings announced that China’s National Medical Products Administration has approved satricabtagene autoleucel (satri-cel), an autologous Claudin18.2-targeted CAR T-cell therapy, for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior treatments. As the first CAR T-cell therapy approved globally for solid tumors, satri-cel could reshape treatment options in high-burden cancers like...

Country Garden Holdings (SEHK:2007) has reported June contracted sales of about CN¥2.45b, down 13% year-on-year. The company also reported weaker first half sales and its first interest payment under a major offshore debt restructuring. See our latest analysis for Country Garden Holdings. The June sales update and progress on offshore debt restructuring come after a mixed price pattern for Country Garden Holdings, with the share price up 8.67% over one day and 10.59% over seven days, but down...

Shanghai Electric Group (SEHK:2727) is back in focus after the Singapore International Arbitration Centre dismissed all substantive claims brought by Oxagon Enterprises with prejudice, reducing legal overhang while leaving profit implications dependent on future enforcement. See our latest analysis for Shanghai Electric Group. Despite the legal win, Shanghai Electric Group’s recent 7 day share price return of 3.89% only partly offsets a 30 day share price decline of 15.98%. However, the 1...

AGM approvals put Deep Source Holdings in focus Deep Source Holdings (SEHK:990) is back on investors’ radar after shareholders approved new company bye laws, director re elections and refreshed share issue and repurchase mandates at the 30 June Annual General Meeting. See our latest analysis for Deep Source Holdings. Despite the supportive AGM outcome, Deep Source Holdings’ recent trading has been mixed. The 1 day share price return of 7.27% and 7 day share price return of 3.51% stand against...

Why ANVISA’s GMP certification matters for WuXi Biologics (Cayman) stock WuXi Biologics (Cayman) (SEHK:2269) has just received GMP certification from Brazil's ANVISA for two Wuxi manufacturing facilities and its packaging center, enabling end to end production of an anti PD L1 cancer immunotherapy. See our latest analysis for WuXi Biologics (Cayman). The ANVISA certification arrives at a time when momentum in WuXi Biologics (Cayman) stock has picked up, with a 1 month share price return of...